期刊文献+

阿可拉定治疗肝细胞癌及其他肿瘤的机制 被引量:2

下载PDF
导出
摘要 <正>肝细胞癌(hepatocellular carcinoma,HCC)占肝原发性肿瘤的90%~[1],在全球范围内以其高发病率、高致死率成为影响人类健康的重大疾病。世界范围肝细胞癌发病率位列恶性肿瘤第七位,死亡率位列恶性肿瘤第三位,仅次于胃癌和肺癌~[2]。目前,早期肝细胞癌的治疗主要采用肿瘤切除、肝移植和肝细胞癌经皮局部消融治疗等方法。
出处 《肝癌电子杂志》 2016年第2期39-43,共5页 Electronic Journal of Liver Tumor
基金 国家重大新药创制项目(2012ZX09101215)
关键词 肝细胞癌 拉定
  • 相关文献

二级参考文献164

  • 1Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Statl activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 1998, 102:1385 - 1392.
  • 2Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcino-genesis in vivo. Proc Natl Acad Sci USA 2000, 97:4227-4232.
  • 3Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998,394:145- 151.
  • 4Gray M J, Zhang J, Ellis LM, et al. HIF- 1 alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005, 24:3110- 3120.
  • 5Loeffler S, Fayard B, Weis J, Weissenberger J. Intedeukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Spl. IntJ Cancer 2005,115:202-213.
  • 6Albanell J, Rojo F, Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol 2001, 28:56-66.
  • 7Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD 1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005,113:109-115.
  • 8Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Group ECO. Phase III randomized trial ofcisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005, 23:8646-8654.
  • 9Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 2005, 5:1085-1093.
  • 10Vincent PW, Bridges A J, Dykes D J, et al. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts. Cancer ChemotherPharmacol 2000, 45:231-238.

共引文献223

同被引文献27

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部